Erlotinib and Temozolomide in Treating Young Patients With Recurrent or Refractory Solid Tumors
Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
This phase I trial is studying the side effects and best dose of erlotinib when given with
temozolomide in treating young patients with recurrent or refractory solid tumors. Erlotinib
may stop the growth of tumor cells by blocking the enzymes necessary for their growth. Drugs
used in chemotherapy, such as temozolomide, work in different ways to stop tumor cells from
dividing so they stop growing or die. Giving erlotinib with temozolomide may kill more tumor
cells.